US FDA 'Uni-Review' Rolls Out: Psychiatric Division Is Among Early Adopters
Executive Summary
Shared review memorandum under Office of New Drugs reorg will help eliminate last-minute surprises between disciplines and provide greater consistency between divisions.
You may also be interested in...
US FDA Integrated Assessment Roll-Out Expanding By End Of 2021
All NMEs and original BLAs are expected to adhere to the team-based review approach by the end of the year, with expansion to other application types later.
US FDA Postmarketing Drug Safety Modernization Plan Will Cut Across Review Disciplines
Detection of nitrosamine impurities in some marketed drugs highlights need for standardized, consistent approach to systematically monitor risks of drugs throughout their lifecycles, CDER’s Janet Woodcock says. Safety monitoring overhaul is lagging behind new drug review modernization effort, but implementation is expected to begin in 2020.
OND Reorg Getting Warm Welcome From Review Divisions
Division directors are embracing the reorganization of US FDA's drug review operations.